Assoc Prof Dr. Min Yu | Tumor Immunity | Best Researcher Award 

Associate Professor/Deputy Chief Physician | Guangdong Provincial People’s Hospital | China

Short Bio:

Min Yu is a distinguished researcher in the field of cancer biology and bioinformatics, currently affiliated with Guangdong Provincial People’s Hospital in Guangzhou, China. 🌟

Profile:

ORCID

Education:

Min Yu completed his foundational education in medicine at a prestigious institution in China, where he developed a strong foundation in clinical practice and patient care. Subsequently, he pursued advanced studies in computational biology and bioinformatics, blending medical expertise with cutting-edge computational techniques.

Experience:

Since joining Guangdong Provincial People’s Hospital in 2014, Min Yu has made significant contributions to the understanding of cancer biology and therapeutic strategies. His work focuses on leveraging computational approaches to decipher complex biological processes underlying cancer development and progression.

Research Interests:

Min Yu’s research interests span several critical areas in cancer biology and bioinformatics, including:

• Liver cancer
• Deep learning applications in oncology
• Pancreatic cancer
• m6A RNA methylation
• Immune checkpoint molecules

His multidisciplinary approach integrates clinical insights with computational methodologies to uncover novel biomarkers and therapeutic targets for various cancer types.

Awards:

Min Yu has been recognized for his outstanding contributions to cancer research and bioinformatics. His awards include accolades for innovative research methodologies and significant advancements in understanding cancer heterogeneity and treatment resistance.

Selected Publications:

1. Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survivalPublished in the International Journal of Cancer in July 2020, this seminal study by Min Yu explores the expression dynamics of key immune checkpoint molecules across diverse cancer types. The research highlights their role in modulating treatment responses, tumor microenvironment characteristics, and patient survival outcomes.Link to Publication: International Journal of Cancer
2. Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survivalPublished in Annals of Translational Medicine in March 2020, Min Yu’s research investigates the landscape of m6A RNA methylation in pancreatic cancer. The study identifies critical m6A-related genes and regulators, shedding light on their impact on disease progression and patient prognosis.Link to Publication: Annals of Translational Medicine
3. A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 CasesFeatured in Disease Markers in February 2020, this comprehensive analysis led by Min Yu delves into the role of the long non-coding RNA (lncRNA) CCAT2 across a diverse spectrum of cancer types. The study’s findings underscore CCAT2’s potential as a universal biomarker and therapeutic target in cancer biology.Link to Publication: Disease Markers
4. Expression Recognition Method Based on a Lightweight Convolutional Neural NetworkPresented in IEEE Access in 2020, Min Yu’s research introduces an innovative approach for gene expression pattern recognition using a lightweight convolutional neural network (CNN). This methodological advancement enhances the accuracy and efficiency of analyzing complex biological datasets, paving the way for improved cancer subtype classification and biomarker discovery.Link to Publication: IEEE Access
5. Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic CancerPublished in Frontiers in Oncology in August 2019, Min Yu’s study investigates alternative splicing patterns across the genome of pancreatic cancer patients. The research identifies prognostic alternative splicing events associated with disease progression and patient outcomes, offering insights into personalized treatment strategies.Link to Publication: Frontiers in Oncology